Joy Feng
- Department of Pediatrics
Associate Professor
- (404) 727-1451
- joy.yang.feng@emory.edu
-
Emory University
HSRB-1 Room E 430
1760 Haygood Drive
Overview
I am an Associate Professor in the Department of Pediatrics and an AssociateDirector in the Division of the Laboratory of Biochemical Pharmacology (LOBP). I joined Emory in February 2025 and brought 25 years of expertise and experience in pre-clinical drug discovery in HIV, HCV, respiratory viruses, and emerging viruses at a leading pharmaceutical company. I am one of the inventors of Remdesivir, the first FDA-approved antiviral to treat COVID, and Obeldesivir, the orally available form under development for emerging viruses. My primary research interests are antiviral nucleoside and nucleotide analogs, viral polymerases, drug resistance, toxicity and off-target evaluation/mechanism of action, and drug metabolizing enzymes/activation pathways, but most importantly, how to advance a drug from bench to bed to address the unmet medical needs.
Research
Publications
-
Lack of activity of HIV-1 integrase strand-transfer inhibitors on recombinase activating gene (RAG) activity at clinically relevant concentrations.
Microbiol Spectr Volume: 13 Page(s): e0246824
01/07/2025 Authors: Demirdjian S; Duong VN; Byrum JN; Nayak A; McKinney CB; Perry JK; Callebaut C; Rodgers KK; Falkard B; Feng JY -
Meeting report of the 37th International Conference on Antiviral Research in Gold Coast, Australia, May 20-24, 2024, organized by the International Society for Antiviral Research.
Antiviral Res Volume: 232 Page(s): 106037
12/01/2024 Authors: Welch SR; Bilello JP; Carter K; Delang L; Dirr L; Durantel D; Feng JY; Gowen BB; Herrero LJ; Janeba Z -
Discovery of GS-7682, a Novel 4'-Cyano-Modified C-Nucleoside Prodrug with Broad Activity against Pneumo- and Picornaviruses and Efficacy in RSV-Infected African Green Monkeys.
J Med Chem Volume: 67 Page(s): 12945 - 12968
08/08/2024 Authors: Siegel DS; Hui HC; Pitts J; Vermillion MS; Ishida K; Rautiola D; Keeney M; Irshad H; Zhang L; Chun K -
Mechanism and spectrum of inhibition of a 4'-cyano modified nucleotide analog against diverse RNA polymerases of prototypic respiratory RNA viruses.
J Biol Chem Volume: 300 Page(s): 107514
08/01/2024 Authors: Gordon CJ; Walker SM; Tchesnokov EP; Kocincova D; Pitts J; Siegel DS; Perry JK; Feng JY; Bilello JP; Gtte M -
The oral nucleoside prodrug GS-5245 is efficacious against SARS-CoV-2 and other endemic, epidemic, and enzootic coronaviruses.
Sci Transl Med Volume: 16 Page(s): eadj4504
05/22/2024 Authors: Martinez DR; Moreira FR; Catanzaro NJ; Diefenbacher MV; Zweigart MR; Gully KL; De la Cruz G; Brown AJ; Adams LE; Yount B -
Discovery of GS-5245 (Obeldesivir), an Oral Prodrug of Nucleoside GS-441524 That Exhibits Antiviral Efficacy in SARS-CoV-2-Infected African Green Monkeys.
J Med Chem Volume: 66 Page(s): 11701 - 11717
09/14/2023 Authors: Mackman RL; Kalla RV; Babusis D; Pitts J; Barrett KT; Chun K; Du Pont V; Rodriguez L; Moshiri J; Xu Y -
Expanded profiling of Remdesivir as a broad-spectrum antiviral and low potential for interaction with other medications in vitro.
Sci Rep Volume: 13 Page(s): 3131
02/23/2023 Authors: Radoshitzky SR; Iversen P; Lu X; Zou J; Kaptein SJF; Stuthman KS; Van Tongeren SA; Steffens J; Gong R; Truong H -
Structural basis for substrate selection by the SARS-CoV-2 replicase.
Nature Volume: 614 Page(s): 781 - 787
02/01/2023 Authors: Malone BF; Perry JK; Olinares PDB; Lee HW; Chen J; Appleby TC; Feng JY; Bilello JP; Ng H; Sotiris J -
Interfering with nucleotide excision by the coronavirus 3'-to-5' exoribonuclease.
Nucleic Acids Res Volume: 51 Page(s): 315 - 336
01/11/2023 Authors: Chinthapatla R; Sotoudegan M; Srivastava P; Anderson TK; Moustafa IM; Passow KT; Kennelly SA; Moorthy R; Dulin D; Feng JY -
The Nucleoside/Nucleotide Analogs Tenofovir and Emtricitabine Are Inactive against SARS-CoV-2.
Molecules Volume: 27
06/30/2022 Authors: Feng JY; Du Pont V; Babusis D; Gordon CJ; Tchesnokov EP; Perry JK; Duong V; Vijjapurapu A; Zhao X; Chan J